Shenglang Pharmaceutical

Hubei Shenglang Pharmaceutical Co., Ltd., commonly known as Shenglang Pharmaceutical, is a leading Chinese pharmaceutical company specializing in the research, development, and large-scale manufacturing of high-end anti-tumor active pharmaceutical ingredients (APIs) and intermediates. Founded in 2012 and headquartered in Xiangyang, Hubei, the company maintains a dedicated R&D center in Shanghai and production facilities in Hubei and Jiangsu. Shenglang Pharmaceutical is a major global supplier of small molecule targeted therapies, providing high-purity versions of widely used oncology generics such as Erlotinib, Gefitinib, Sunitinib, and Imatinib. The company's portfolio focuses on critical pathways in cancer treatment, including EGFR, VEGFR, and BCR-ABL inhibitors. Recognized as a high-tech enterprise, Shenglang Pharmaceutical serves a global clientele of pharmaceutical companies by delivering registered APIs and specialized chemical intermediates for complex oncology treatments.